MedPage Today on MSN
Race for the Rheum Disease Cure Heats Up
For starters, she pointed out that standard CAR-T therapy involves a lymphodepletion regimen with cyclophosphamide and ...
Researchers released a consensus statement with recommendations to update T cell nomenclature and improve communication ...
Universal CAR T cells produce rapid remissions and enable allogeneic stem cell transplants in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
News Medical on MSN
Johns Hopkins Scientists Develop Targeted Therapy for T-Cell Lymphomas and Leukemias
Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...
Multiple myeloma is an incurable plasma cell malignancy despite major therapeutic advances. A recent review by Chinese ...
On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...
News-Medical.Net on MSN
Remodeling the tumor microenvironment to unlock CAR-T cell potential
Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback